Effective Chemo-Free Therapy: Brentuximab Vedotin Plus Nivolumab Yields Durable Response in Older Hodgkin Lymphoma

In this phase II study targeting patients over 60 or those unfit for standard chemotherapy, the combination of brentuximab vedotin (BV) and nivolumab demonstrated promising long-term outcomes. With a median follow-up of nearly 5 years, the median overall survival has not yet been reached, and about 41% of patients remain progression-free.

These results confirm that a chemo-free BV-nivolumab regimen can achieve durable disease control and excellent survival in older HL patients, paving the way for further optimization and integration of novel agents for this challenging population.